Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Marielle J
MJ
Wondergem
Josee M
JM
Zijlstra
Madelon
M
de Rooij
Otto J
OJ
Visser
Peter C
PC
Huijgens
Sonja
S
Zweegman
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D008558:Melphalan / Q000627:therapeutic use; D016499:Radioimmunotherapy / Q000379:methods*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; D003561:Cytarabine; C422802:ibritumomab tiuxetan; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine